Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
4 "Eun Chang Choi"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Survival and Functional Outcome after Treatment for Primary Base of Tongue Cancer: A Comparison of Definitive Chemoradiotherapy versus Surgery Followed by Adjuvant Radiotherapy
Sangjoon Park, Yeona Cho, Jeongshim Lee, Yoon Woo Koh, Se-Heon Kim, Eun Chang Choi, Hye Ryun Kim, Ki Chang Keum, Kyung Ran Park, Chang Geol Lee
Cancer Res Treat. 2018;50(4):1214-1225.   Published online December 26, 2017
DOI: https://doi.org/10.4143/crt.2017.498
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to compare the clinical and functional outcomes in patients with primary base of tongue (BOT) cancer who received definitive radiotherapy (RT) or surgery followed by radiotherapy (SRT).
Materials and Methods
Between January 2002 andDecember 2016, 102 patientswith stage I-IVB primary BOT cancer underwent either definitive RT (n=46) or SRT (n=56), and treatment outcomeswere compared between two groups. The expression of p16 was also analyzed.
Results
The RT group had more patients with advanced T stage (T3-4) disease (58.7% vs. 35.7%, p=0.021) and who received chemotherapy (91.3% vs. 37.5%, p < 0.001) than the SRT group. At a median followup of 36.9 months (range, 3.3 to 181.5 months), the 5-year overall survival (OS) and disease-free survival (DFS) were 75.5% and 68.7%, respectively. With respect to treatment group, the 5-year OS and DFS in the RT and SRT groups did not differ significantly (OS, 68.7% vs. 80.5%, p=0.601; DFS, 63.1% vs. 73.1%, p=0.653). In multivariate analysis, OS differed significantly according to p16 expression (p16-negative vs. p16- positive; hazard ratio [HR], 0.145; 95% confidence interval [CI], 0.025 to 0.853; p=0.033). Regarding DFS, p16 expression (p16-negative vs. p16-positive; HR, 0.164; 95% CI, 0.045 to 0.598; p=0.006) showed a significant effect in multivariate analysis. Functional defects (late grade ≥ 3 dysphagia or voice alteration) were more frequently reported in the SRT than in the RT group (16.1% vs. 2.2%, p=0.021).
Conclusion
Despite advanced disease, patients in the RT group showed comparable survival outcomes and better functional preservation than those in the SRT group.

Citations

Citations to this article as recorded by  
  • Treatment de‐escalation for HPV+ oropharyngeal cancer: A systematic review and meta‐analysis
    Fausto Petrelli, Andrea Luciani, Antonio Ghidini, Sara Cherri, Paolo Gamba, Marta Maddalo, Paolo Bossi, Alberto Zaniboni
    Head & Neck.2022; 44(5): 1255.     CrossRef
  • Ginsenoside Rd inhibits migration and invasion of tongue cancer cells through H19/miR-675-5p/CDH1 axis
    Lu CHANG, Dongxu WANG, Shaoning KAN, Ming HAO, Huimin LIU, Zhijing YANG, Qianyun XIA, Weiwei LIU
    Journal of Applied Oral Science.2022;[Epub]     CrossRef
  • Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Oral Cavity Cancer in the Era of Modern Radiation Techniques
    Tae Hyung Kim, In-Ho Cha, Eun Chang Choi, Hye Ryun Kim, Hyung Jun Kim, Se-Heon Kim, Ki Chang Keum, Chang Geol Lee
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Superficial circumflex iliac artery perforator flap for tongue reconstruction after hemiglossectomy for cancer: A case report
    Hong Loi Nguyen, Truong Phu M. Ho, Xuan Phu Tran, Thanh Xuan Nguyen
    Oral and Maxillofacial Surgery Cases.2021; 7(2): 100219.     CrossRef
  • Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
    Ambika Parmar, Michaelina Macluskey, Niall Mc Goldrick, David I Conway, Anne-Marie Glenny, Janet E Clarkson, Helen V Worthington, Kelvin KW Chan
    Cochrane Database of Systematic Reviews.2021;[Epub]     CrossRef
  • Larynx-preserving reconstruction after extended base of the tongue resection
    Hideki Kadota, Junichi Fukushima, Sei Yoshida, Kenichi Kamizono, Muneyuki Masuda, Satoshi Toh, Ryuji Yasumatsu, Torahiko Nakashima, Takashi Nakagawa
    Journal of Plastic, Reconstructive & Aesthetic Surgery.2020; 73(4): 740.     CrossRef
  • 9,805 View
  • 228 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
Radiotherapy Versus Cordectomy in the Management of Early Glottic Cancer
Seung Yeun Chung, Kyung Hwan Kim, Ki Chang Keum, Yoon Woo Koh, Se-Heon Kim, Eun Chang Choi, Chang Geol Lee
Cancer Res Treat. 2018;50(1):156-163.   Published online March 17, 2017
DOI: https://doi.org/10.4143/crt.2016.503
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to compare the treatment outcomes of definitive radiotherapy (RT) with cordectomy in patients with early glottic cancer.
Materials and Methods
A total of 165 patientswhowere diagnosedwith T1/2 squamous cell carcinoma of the glottic larynx between January 2006 and December 2012 were retrospectively analyzed. A total of 112 patients received RT and 53 patients received cordectomy. Local control (LC), disease-free survival (DFS), overall survival (OS), and larynx preservation rates after RT and cordectomy were investigated.
Results
The median follow-up period was 77.7 months (range, 10.7 to 127.0 months). The 3- and 5-year LC rates were 91.9% and 89.9%, respectively, for the RT group, and 82.8% and 73.2%, respectively, for the cordectomy group (p=0.006). The 3- and 5-year DFS rates were 87.5% and 83.7%, respectively, for the RT group and 79.2% and 68.0%, respectively, for the cordectomy group (p=0.046). No significant differences were identified in the 5-year OS (92.8% vs. 90.6%, p=0.713) or larynx preservation rates (98.2% vs. 97.2%, p=0.831) between groups. The major failure pattern was local failure (n=26), followed by regional (n=3) and distant failure (n=2). Multivariate analysis of LC showed that T2 stage (p=0.012) and receiving cordectomy as initial treatment (p=0.001) were significantly associated with poorer LC.
Conclusion
RT resulted in higher rates of LC and DFS compared to cordectomy for early glottic cancer. Treatment with radiotherapy is feasible and should be encouraged for both T1 and T2 glottic cancer.

Citations

Citations to this article as recorded by  
  • Particular aspects of laser microsurgery in malignant and premalignant glottic lesions
    Mihai Tușaliu, Costinel Adrian Vrejoiu, Iulia Tiţă, Mădălina Vulpe, Adriana Lozbă, Cristian Bucur
    ORL.ro.2024; 1(62): 9.     CrossRef
  • Oncological outcomes of surgical management for T2N0M0 glottic laryngeal squamous cell carcinoma
    Jian Zhou, Cheng‐Zhi Xu, Xiao‐Ke Zhu, Yue Yang, Liang Zhou, Hong‐Li Gong, Lei Tao
    World Journal of Otorhinolaryngology - Head and Neck Surgery.2024;[Epub]     CrossRef
  • The association between initiation weekday of radiotherapy and local control in stage 1 glottic carcinoma: a retrospective analysis
    Masashi Endo, Satoru Takahashi, Yukiko Fukuda, Kohei Okada, Kazunari Ogawa, Michiko Nakamura, Masahiro Kawahara, Keiko Akahane, Eri Murakami, Chiaki Shibayama, Ryutaro Onaga, Takafumi Nagatomo, Takeharu Kanazawa, Hiroshi Nishino, Harushi Mori, Katsuyuki S
    Journal of Radiation Research.2024; 65(6): 798.     CrossRef
  • The Same–Up–Down Staging System for Recurrent Early Glottic Cancer
    Giuseppe Licci, Luca Giovanni Locatello, Giandomenico Maggiore, Flavia Cozzolino, Saverio Caini, Oreste Gallo
    Cancers.2023; 15(3): 598.     CrossRef
  • Kehlkopfteilresektion – eine interdisziplinäre Gratwanderung zwischen Resektion und Funktionserhalt
    Manuel Christoph Ketterer, Rainer Beck, Matthias Cohnen, Andreas Knopf
    best practice onkologie.2023; 18(5): 184.     CrossRef
  • Intensity-Modulated Radiation Therapy for Early-Stage Squamous Cell Carcinoma of the Glottic Larynx: A Systematic Review and Meta-Analysis
    Niema B. Razavian, Ralph B. D'Agostino, Rachel F. Shenker, Ryan T. Hughes
    International Journal of Radiation Oncology*Biology*Physics.2023; 117(3): 652.     CrossRef
  • Clinical Analysis of the Treatment Outcomes of Laryngeal Cancer
    Takashi Kurita, Shun-ichi Chitose, Takeharu Ono, Mioko Fukahori, Shintaro Sueyoshi, Ryota Mihashi, Toshihiko Kawaguchi, Akira Hiraki, Hirohito Umeno
    Practica oto-rhino-laryngologica. Suppl..2023; 163: 89.     CrossRef
  • Comparison of Survival Outcomes of Different Treatment Options for cT1-2, N0 Glottic Carcinoma: A Propensity Score–Weighted Analysis
    Qi-wei Liang, Liang Peng, Jing Liao, Chun-xia Huang, Wei-ping Wen, Wei Sun
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • Survival study in early stages of glottis cancer, stratified by treatment
    Yolanda Lois-Ortega, Fernando García-Curdi, Héctor Vallés-Varela, Ana Muniesa-del Campo
    Acta Oto-Laryngologica.2022; 142(7-8): 627.     CrossRef
  • Selective local postoperative radiotherapy for T3–T4 N0 laryngeal cancer
    Meltem Dağdelen, Merve Şahin, Tuba Kurt Çatal, Halil Cumhur Yıldırım, Songül Çavdar Karaçam, Kimia Çepni, Ömer Erol Uzel
    Strahlentherapie und Onkologie.2022; 198(11): 1025.     CrossRef
  • Long-term impact of smoking cessation on new glottic cancer events in patients with early glottic cancer
    Min-Su Kim, Hong-Gyun Wu, Myung-Whun Sung, Tack-Kyun Kwon
    Acta Otorhinolaryngologica Italica.2022; 42(6): 525.     CrossRef
  • Diode Laser for Laryngeal Cancer: “980 nm” and Beyond the Classic CO2
    Petros D. Karkos, Ioannis Koskinas, Marios Stavrakas, Stefanos Triaridis, Jannis Constantinidis
    Ear, Nose & Throat Journal.2021; 100(1_suppl): 19S.     CrossRef
  • Radiotherapy versus partial laryngectomy in the management of early glottic cancer with anterior commissure involvement: A propensity score matched study with 256 patients
    Ruichen Li, Qi Wang, Li Yan, Yi Zhu, Shengzi Wang, Shu Tian
    Oral Oncology.2021; 116: 105230.     CrossRef
  • Could Primary Chemoradiotherapy in T2 Glottic Cancers Yield Results Comparable to Primary Radiotherapy in T1? Considerations from 531 German Early Stage Patients
    Gerhard Dyckhoff, Rolf Warta, Christel Herold-Mende, Elisabeth Rudolph, Peter K. Plinkert, Heribert Ramroth
    Cancers.2021; 13(7): 1601.     CrossRef
  • Age as Indicator in the Selection of Surgery Modalities in Early Glottic Cancer
    Jialing Wu, Kaiyun You, Xingsheng Qiu, Ting Shen, Juanjuan Song, Changlong Chen, Yanhui Jiang, Yimin Liu
    Risk Management and Healthcare Policy.2021; Volume 14: 3223.     CrossRef
  • Feasibility of single vocal cord irradiation as a treatment strategy for T1a glottic cancer
    Seung Yeun Chung, Chang Geol Lee
    Head & Neck.2020; 42(5): 854.     CrossRef
  • Radiotherapy versus laser microsurgery in the treatment of early glottic cancer
    Yolanda Lois-Ortega, Fernando García-Curdi, José Miguel Sebastián-Cortés, Félix De Miguel-García, Héctor Vallés-Varela, Ana Muniesa-del Campo
    Acta Oto-Laryngologica.2020; 140(11): 954.     CrossRef
  • Radiotherapy Versus Surgery–Which Is Better for Patients With T1-2N0M0 Glottic Laryngeal Squamous Cell Carcinoma? Individualized Survival Prediction Based on Web-Based Nomograms
    Yajing Du, Shali Shao, Minghe Lv, Yi Zhu, Li Yan, Tiankui Qiao
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Comparison between radiotherapy and transoral laser microsurgery treatments in early-stages of glottis cancer: A five-year follow-up study
    Javier Santabárbara
    Investigación Clínica.2020; 61(4): 324.     CrossRef
  • Prospective validation of an institutional treatment strategy for T1N0M0 glottic carcinoma
    Simon Beyaert, Marc Hamoir, Aline Van Maanen, Vincent Grégoire, Sandra Schmitz
    European Journal of Surgical Oncology.2019; 45(7): 1188.     CrossRef
  • Prognostic factors in patients with T1 glottic cancer treated with radiotherapy
    A. Mucha-Małecka, A. Chrostowska, K. Urbanek, K. Małecki
    Strahlentherapie und Onkologie.2019; 195(9): 792.     CrossRef
  • Involvement of the Anterior Commissure in Early Glottic Cancer (Tis-T2): A Review of the Literature
    Martine Hendriksma, Elisabeth V. Sjögren
    Cancers.2019; 11(9): 1234.     CrossRef
  • Treatment of early-stage laryngeal cancer: A comparison of treatment options
    Brandon Jackson Baird, C. Kwang Sung, Beth M. Beadle, Vasu Divi
    Oral Oncology.2018; 87: 8.     CrossRef
  • 9,888 View
  • 404 Download
  • 22 Web of Science
  • 23 Crossref
Close layer
Tumor Stage-Related Role of Radiotherapy in Patients with an External Auditory Canal and Middle Ear Carcinoma
Jinhyun Choi, Se-Heon Kim, Yoon Woo Koh, Eun Chang Choi, Chang Geol Lee, Ki Chang Keum
Cancer Res Treat. 2017;49(1):178-184.   Published online July 4, 2016
DOI: https://doi.org/10.4143/crt.2016.165
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to evaluate the clinical outcomes of patients treated with radiotherapy (RT) for a carcinoma of the external auditory canal (EAC) and middle ear.
Materials and Methods
The records of 32 patients who received RT from 1990 to 2013 were reviewed retrospectively. The Pittsburgh classification was used to stage all the cancers (early stage, T1/T2 [n=12]; advanced stage, T3/T4 or N positive [n=20]). Twenty-one patients (65.6%) were treated with postoperative RT and 11 patients (34.4%) were treated with definitive RT. The median radiation doses for postoperative and definitive RT were 60 Gy and 64.8 Gy, respectively. Chemotherapy was administered to seven patients (21.9%).
Results
The 5-year overall survival and disease-free survival rates for all patients were 57% and 52%, respectively. The disease control rates for the patients with early stage versus advanced stage carcinomawere 55.6% (5/9) and 50% (6/12) in the postoperative RT group and 66.7% (2/3) and 37.5% (3/8) in the definitive RT group, respectively. Overall, 15 cases (14 patients, 46.7%) experienced treatment failure; these failures were classified as local in four cases, regional in one case, and distant in 10 cases. The median follow-up period after RT was 51 months (range, 7 to 286 months).
Conclusion
Patients with early stage carcinoma achieved better outcomes when definitive RT was used. Advanced stage carcinoma patients experienced better outcomes with postoperative RT. The high rate of distant failure after RT, with or without surgery, reflected the lack of a consensus regarding the best therapeutic approach for treating carcinoma of the EAC and middle ear.

Citations

Citations to this article as recorded by  
  • Survival Outcomes of Temporal Bone Squamous Cell Carcinoma: A Systematic Review and Meta‐Analysis
    Krystelle Sioufi, Aaron David Haynes, Paul W. Gidley, Anastasios Maniakas, Dianna Roberts, Marc‐Elie Nader
    Otolaryngology–Head and Neck Surgery.2024; 171(1): 1.     CrossRef
  • The international expert consensus on management of external auditory canal carcinoma
    Pei Zhou, Rubens de Brito, Yong Cui, Simon Lloyd, Henricus Kunst, J. Walter Kutz, Navin Mani, In Seok Moon, Badr Eldin Mostafa, Cindy Nabuurs, Sampath Chandra Prasad Rao, Bingbin Xie, Yibo Zhang, Chunfu Dai
    European Archives of Oto-Rhino-Laryngology.2024;[Epub]     CrossRef
  • Postoperative Radiotherapy for pT1- and pT2-Classified Squamous Cell Carcinoma of the External Auditory Canal
    Cindy Nabuurs, Wietske Kievit, Charles Leemans, Conrad Smit, Michiel van den Brekel, Robert Pauw, Bernard van der Laan, Jeroen Jansen, Martin Lacko, Weibel Braunius, Chunfu Dai, Xunbei Shi, Giovanni Danesi, Jan Bouček, Daniele Borsetto, Shravan Gowrishank
    Cancers.2024; 16(23): 4026.     CrossRef
  • Clinical outcomes of temporal bone squamous cell carcinoma: A single‐institution experience
    Yongbo Zheng, Ke Qiu, Yangju Fu, Wenjie Yang, Danni Cheng, Yufang Rao, Minzi Mao, Yao Song, Wei Xu, Jianjun Ren, Yu Zhao
    Cancer Medicine.2023; 12(5): 5304.     CrossRef
  • Analysis of Prognostic Factors For External Auditory Canal Carcinoma: A 22‐Year Experience
    Isabelle J. H. Jang, Jiun Fong Thong, Constance E. H. Teo, Kiattisa Sommat
    The Laryngoscope.2023; 133(9): 2203.     CrossRef
  • Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: Expecting Its Application in Temporal Bone Squamous Cell Carcinoma
    Meng-wen Shi, Jing Huang, Yu Sun
    Current Medical Science.2023; 43(2): 213.     CrossRef
  • Preoperative simulation using three‐dimensional printer in four temporal bone surgeries
    Ichiro Fukumoto, Yukiyoshi Mita, Rie Shimmi, Yuri Sonobe, Tomohisa Iinuma, Kazuki Yamasaki, Shuji Yonekura, Toshimitsu Nemoto, Toyoyuki Hanazawa
    Clinical Case Reports.2023;[Epub]     CrossRef
  • The Efficacy of Radiotherapy without Surgery for External Auditory Canal Squamous Cell Carcinoma
    Naoto Osu, Atsushi Musha, Hikaru Yumisaki, Kohei Okada, Nobuteru Kubo, Naoko Okano, Yukihiko Takayasu, Masato Shino, Osamu Nikkuni, Shota Ida, Hidemasa Kawamura, Kazuaki Chikamatsu, Tatsuya Ohno
    Journal of Clinical Medicine.2022; 11(19): 5905.     CrossRef
  • Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma
    Ke Qiu, Wendu Pang, Jianqing Qiu, Junhong Li, Danni Cheng, Yufang Rao, Yijun Dong, Minzi Mao, Qiurui Liu, Xiaosong Mu, Wei Zhang, Wei Xu, Jianjun Ren, Yu Zhao
    Cancer Medicine.2021; 10(22): 7958.     CrossRef
  • Evaluation of the modified Pittsburgh classification for predicting the disease‐free survival outcome of squamous cell carcinoma of the external auditory canal
    Cindy H. Nabuurs, Wietske Kievit, Nilou Labbé, C. René Leemans, Conrad F. G. M. Smit, Michiel W. M. van den Brekel, Robert J. Pauw, Bernard F. A. M. van der Laan, Jeroen C. Jansen, Martin Lacko, Weibel W. Braunius, Shinya Morita, Małgorzata Wierzbicka, Ta
    Head & Neck.2020; 42(12): 3609.     CrossRef
  • Management of Temporal Bone Malignancy in Ireland
    Robbie S. R. Woods, Anel Naude, John Barry O'Sullivan, Daniel Rawluk, Mohsen Javadpour, Peter Walshe, Peter D. Lacy, James Paul O'Neill, Rory McConn-Walsh
    Journal of Neurological Surgery Part B: Skull Base.2020; 81(06): 680.     CrossRef
  • A retrospective multicenter study of carbon‐ion radiotherapy for external auditory canal and middle ear carcinomas
    Kazuhiko Hayashi, Masashi Koto, Yusuke Demizu, Jun‐ichi Saitoh, Hiroaki Suefuji, Tomoaki Okimoto, Tatsuya Ohno, Yoshiyuki Shioyama, Ryo Takagi, Hiroaki Ikawa, Kenji Nemoto, Takashi Nakano, Tadashi Kamada
    Cancer Medicine.2019; 8(1): 51.     CrossRef
  • Squamous cell carcinoma of the temporal bone: A current review
    Benjamin D. Lovin, Paul W. Gidley
    Laryngoscope Investigative Otolaryngology.2019; 4(6): 684.     CrossRef
  • Carcinoma of middle ear
    Dragoslava Đerić
    Биомедицинска истраживања.2019; 10(2): 179.     CrossRef
  • Surgery With or Without Postoperative Radiation Therapy for Early-stage External Auditory Canal Squamous Cell Carcinoma: A Meta-analysis
    Ryohei Oya, Yukinori Takenaka, Kazuya Takemura, Naoki Ashida, Kotaro Shimizu, Takahiro Kitamura, Yoshifumi Yamamoto, Atsuhiko Uno
    Otology & Neurotology.2017; 38(9): 1333.     CrossRef
  • 10,259 View
  • 240 Download
  • 16 Web of Science
  • 15 Crossref
Close layer
Anti-cancer Effect of Luminacin, a Marine Microbial Extract, in Head and Neck Squamous Cell Carcinoma Progression via Autophagic Cell Death
Yoo Seob Shin, Hyun Young Cha, Bok-Soon Lee, Sung Un Kang, Hye Sook Hwang, Hak Cheol Kwon, Chul-Ho Kim, Eun Chang Choi
Cancer Res Treat. 2016;48(2):738-752.   Published online September 9, 2015
DOI: https://doi.org/10.4143/crt.2015.102
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to determine whether luminacin, a marine microbial extract from the Streptomyces species, has anti-tumor effects on head and neck squamous cell carcinoma (HNSCC) cell lines via autophagic cell death. Materials and Methods Inhibition of cell survival and increased cell death was measured using cell viability, colony forming, and apoptosis assays. Migration and invasion abilities of head and cancer cells were evaluated using wound healing, scattering, and invasion assays. Changes in the signal pathway related to autophagic cell death were investigated. Drug toxicity of luminacin was examined in in vitro HaCaT cells and an in vivo zebrafish model.
Results
Luminacin showed potent cytotoxicity in HNSCC cells in cell viability, colony forming, and fluorescence-activated cell sorting analysis. In vitro migration and invasion of HNSCC cells were attenuated by luminacin treatment. Combined with Beclin-1 and LC3B, Luminacin induced autophagic cell death in head and neck cancer cells. In addition, in a zebrafish model and human keratinocyte cell line used for toxicity testing, luminacin treatment with a cytotoxic concentration to HNSCC cells did not cause toxicity. Conclusion Taken together, these results demonstrate that luminacin induces the inhibition of growth and cancer progression via autophagic cell death in HNSCC cell lines, indicating a possible alternative chemotherapeutic approach for treatment of HNSCC.

Citations

Citations to this article as recorded by  
  • Sam68 is a druggable vulnerability point in cancer stem cells
    Amanda Mendes da Silva, Veronika Yevdokimova, Yannick D. Benoit
    Cancer and Metastasis Reviews.2024; 43(1): 441.     CrossRef
  • Marine endophytes from the Indian coasts: The untapped sources of sustainable anticancer drug discovery
    Siya Kamat, Madhuree Kumari, Kuttuvan Valappil Sajna, Shruthi Mohan, C. Jayabaskaran
    Sustainable Chemistry and Pharmacy.2022; 27: 100675.     CrossRef
  • The Zebrafish model in dermatology: an update for clinicians
    Irene Russo, Emma Sartor, Laura Fagotto, Anna Colombo, Natascia Tiso, Mauro Alaibac
    Discover Oncology.2022;[Epub]     CrossRef
  • Marine Bioactive Compounds as Nutraceutical and Functional Food Ingredients for Potential Oral Health
    Yi-Zhen Huang, Zheng Jin, Zhe-Ming Wang, Li-Bo Qi, Shuang Song, Bei-Wei Zhu, Xiu-Ping Dong
    Frontiers in Nutrition.2021;[Epub]     CrossRef
  • Bacillus pumilus Ribonuclease Inhibits Migration of Human Duodenum Adenocarcinoma HuTu 80 Cells
    P. V. Zelenikhin, I. S. Ead Mohamed, A. I. Nadyrova, A. A. Sirotkina, V. V. Ulyanova, N. L. Mironova, V. A. Mitkevich, A. A. Makarov, M. A. Zenkova, O. N. Ilinskaya
    Molecular Biology.2020; 54(1): 128.     CrossRef
  • The anti-alcohol dependency drug disulfiram inhibits the viability and progression of gastric cancer cells by regulating the Wnt and NF-κB pathways
    Jun Zhang, Ke Pu, Suyang Bai, Yukui Peng, Fan Li, Rui Ji, Qinghong Guo, Weiming Sun, Yuping Wang
    Journal of International Medical Research.2020;[Epub]     CrossRef
  • Autophagy-Related Beclin 1 and Head and Neck Cancers


    Yang-Jie Hu, Jiang-Tao Zhong, Liang Gong, Si-Cong Zhang, Shui-Hong Zhou
    OncoTargets and Therapy.2020; Volume 13: 6213.     CrossRef
  • Blue-Print Autophagy in 2020: A Critical Review
    Sergey A. Dyshlovoy
    Marine Drugs.2020; 18(9): 482.     CrossRef
  • The Link of Marine Products with Autophagy-Associated Cell Death in Cancer Cell
    Teresa Liliana Wargasetia, Nashi Widodo
    Current Pharmacology Reports.2019; 5(1): 35.     CrossRef
  • Non-thermal plasma inhibits mast cell activation and ameliorates allergic skin inflammatory diseases in NC/Nga mice
    Myung-Hoon Lee, Yun Sang Lee, Haeng Jun Kim, Chang Hak Han, Sung Un Kang, Chul-Ho Kim
    Scientific Reports.2019;[Epub]     CrossRef
  • HSPA5 negatively regulates lysosomal activity through ubiquitination of MUL1 in head and neck cancer
    Sun-Yong Kim, Hyo Jeong Kim, Haeng-Jun Kim, Dae Ho Kim, Jae Ho Han, Hyung Kwon Byeon, Keunho Lee, Chul-Ho Kim
    Autophagy.2018; 14(3): 385.     CrossRef
  • HDAC4 degradation by combined TRAIL and valproic acid treatment induces apoptotic cell death of TRAIL-resistant head and neck cancer cells
    Bok-Soon Lee, Yeon Soo Kim, Haeng-Jun Kim, Dae-Ho Kim, Ho-Ryun Won, Yong-Sung Kim, Chul-Ho Kim
    Scientific Reports.2018;[Epub]     CrossRef
  • Controlled Release of Hepatocyte Growth Factor from MPEG-b-(PCL-ran-PLLA) Diblock Copolymer for Improved Vocal Fold Regeneration
    Jae Won Choi, Yeon Soo Kim, Ju Kyeong Park, Eun Hye Song, Ji Hoon Park, Moon Suk Kim, Yoo Seob Shin, Chul-Ho Kim
    Macromolecular Bioscience.2017; 17(2): 1600163.     CrossRef
  • Preclinical models in HNSCC: A comprehensive review
    Benoite Méry, Chloé Rancoule, Jean-Baptiste Guy, Sophie Espenel, Anne-Sophie Wozny, Priscilla Battiston-Montagne, Dominique Ardail, Michael Beuve, Gersende Alphonse, Claire Rodriguez-Lafrasse, Nicolas Magné
    Oral Oncology.2017; 65: 51.     CrossRef
  • Marine actinobacteria as a drug treasure house
    Syed Shams ul Hassan, Abdul Lateef Shaikh
    Biomedicine & Pharmacotherapy.2017; 87: 46.     CrossRef
  • Zebrafish as a Model Organism for the Development of Drugs for Skin Cancer
    Fatemeh Bootorabi, Hamed Manouchehri, Reza Changizi, Harlan Barker, Elisabetta Palazzo, Annalisa Saltari, Mataleena Parikka, Carlo Pincelli, Ashok Aspatwar
    International Journal of Molecular Sciences.2017; 18(7): 1550.     CrossRef
  • 13,218 View
  • 167 Download
  • 17 Web of Science
  • 16 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP